Skip to main content

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

New app tracks Health of Heart and Lung patients

A new smartphone app that monitors patients suffering from chronic cardiopulmonary diseases by analysing the way they walk can warn doctors at the first sign of trouble. Using the health-tracking app, MoveSense, developed by researchers at the University of Illinois at Urbana-Champaign, a patient's oxygen saturation level can be passively monitored with medical accuracy. Oxygen saturation is a standard measure of health status.

IGMPI wins QCI - D. L. Shah Quality Award 2015 - Certificate of Merit

  • Certificate of Merit for an initiative for knowledge dissemination & training in the area of good manufacturing practices (GMP) By Dr. R. P. Singh (Secretary general, QCI) and Mr. Hari K. Taneja (Trustee, D.L.Shah Trust) in 10th National Quality Conclave held on August 7-8, 2015 at Sirifort Auditorium, New Delhi.

The Annual Flagship event of QCI, the 10th National Quality Conclave “Creating an Ecosystem for World Class Quality in India” with World Health Organization (as Technical Partner for Health Thematic Session) and ASQ (as the Knowledge Partner) held on August 7-8, 2015 in New Delhi. The Quality Conclave 2015 is a platform to know what the world has done and how India can build an Ecosystem of Quality in every sphere of life.


Hetero introduce Maball for NHL, CLL patients in India

Hetero Group, one of India’s leading generic pharmaceutical companies  has recently announced the launch of its biosimilar ‘Rituximab’ under the brand name Maball in India. It will be marketed and distributed by Hetero Healthcare Limited, a group company of Hetero. Rituximab is recommended as the first-line treatment for NHL and is available in a single dose vial with two strengths – 100mg/10ml and 500mg/50ml.

Ajanta Pharma receives US FDA final approval for generic Singulair tablets

Ajanta Pharma Limited, a Rs.1,450 crore plus Mumbai based specialty focused pharmaceutical formulation company, has received final approval from the United States Food and Drug Administration (FDA)  for its 3 Abbreviated New Drug Applications (ANDAs), montelukast tablets, 10mg,  montelukast sodium chewable tablets, 4mg & 5mg and montelukast oral granules.

Subscribe to Pharma News